BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28177577)

  • 1. Award Winner in the Young Investigator Category, 2017 Society for Biomaterials Annual Meeting and Exposition, Minneapolis, MN, April 05-08, 2017: Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner.
    Apoorva FNU; Tian YF; Pierpont TM; Bassen DM; Cerchietti L; Butcher JT; Weiss RS; Singh A
    J Biomed Mater Res A; 2017 Jul; 105(7):1833-1844. PubMed ID: 28177577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
    Tian YF; Ahn H; Schneider RS; Yang SN; Roman-Gonzalez L; Melnick AM; Cerchietti L; Singh A
    Biomaterials; 2015 Dec; 73():110-9. PubMed ID: 26406451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Student award for outstanding research winner in the Ph.D. category for the 2017 society for biomaterials annual meeting and exposition, april 5-8, 2017, Minneapolis, Minnesota: Characterization of protein interactions with molecularly imprinted hydrogels that possess engineered affinity for high isoelectric point biomarkers.
    Clegg JR; Zhong JX; Irani AS; Gu J; Spencer DS; Peppas NA
    J Biomed Mater Res A; 2017 Jun; 105(6):1565-1574. PubMed ID: 28177574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas.
    Marmey B; Boix C; Barbaroux JB; Dieu-Nosjean MC; Diebold J; Audouin J; Fridman WH; Mueller CG; Molina TJ
    Hum Pathol; 2006 Jan; 37(1):68-77. PubMed ID: 16360418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Biophysical Forces Regulate Human B Cell Lymphomas.
    Apoorva F; Loiben AM; Shah SB; Purwada A; Fontan L; Goldstein R; Kirby BJ; Melnick AM; Cosgrove BD; Singh A
    Cell Rep; 2018 Apr; 23(2):499-511. PubMed ID: 29642007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á
    Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
    Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
    Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL10 receptor is a novel therapeutic target in DLBCLs.
    Béguelin W; Sawh S; Chambwe N; Chan FC; Jiang Y; Choo JW; Scott DW; Chalmers A; Geng H; Tsikitas L; Tam W; Bhagat G; Gascoyne RD; Shaknovich R
    Leukemia; 2015 Aug; 29(8):1684-94. PubMed ID: 25733167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Hodgkin's lymphoma: the old and the new.
    Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of matrix stiffness on the behavior of brain metastatic breast cancer cells in a biomimetic hyaluronic acid hydrogel platform.
    Narkhede AA; Crenshaw JH; Manning RM; Rao SS
    J Biomed Mater Res A; 2018 Jul; 106(7):1832-1841. PubMed ID: 29468800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
    Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
    Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.
    Matthews JM; Bhatt S; Patricelli MP; Nomanbhoy TK; Jiang X; Natkunam Y; Gentles AJ; Martinez E; Zhu D; Chapman JR; Cortizas E; Shyam R; Chinichian S; Advani R; Tan L; Zhang J; Choi HG; Tibshirani R; Buhrlage SJ; Gratzinger D; Verdun R; Gray NS; Lossos IS
    Blood; 2016 Jul; 128(2):239-48. PubMed ID: 27151888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas.
    Mircean C; Tabus I; Kobayashi T; Yamaguchi M; Shiku H; Shmulevich I; Zhang W
    Int J Oncol; 2004 Mar; 24(3):497-504. PubMed ID: 14767533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation.
    Singh RR; Kim JE; Davuluri Y; Drakos E; Cho-Vega JH; Amin HM; Vega F
    Leukemia; 2010 May; 24(5):1025-36. PubMed ID: 20200556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
    Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
    Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.